1258 related articles for article (PubMed ID: 30924399)
1. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
[No Abstract] [Full Text] [Related]
2. Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score.
Lim YY; Snyder PJ; Pietrzak RH; Ukiqi A; Villemagne VL; Ames D; Salvado O; Bourgeat P; Martins RN; Masters CL; Rowe CC; Maruff P
Alzheimers Dement (Amst); 2016; 2():19-26. PubMed ID: 27239532
[TBL] [Abstract][Full Text] [Related]
3. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.
Donohue MC; Sperling RA; Salmon DP; Rentz DM; Raman R; Thomas RG; Weiner M; Aisen PS; ; ;
JAMA Neurol; 2014 Aug; 71(8):961-70. PubMed ID: 24886908
[TBL] [Abstract][Full Text] [Related]
4. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
5. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.
Mormino EC; Papp KV; Rentz DM; Donohue MC; Amariglio R; Quiroz YT; Chhatwal J; Marshall GA; Donovan N; Jackson J; Gatchel JR; Hanseeuw BJ; Schultz AP; Aisen PS; Johnson KA; Sperling RA
Alzheimers Dement; 2017 Sep; 13(9):1004-1012. PubMed ID: 28253478
[TBL] [Abstract][Full Text] [Related]
6. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.
Papp KV; Rofael H; Veroff AE; Donohue MC; Wang S; Randolph C; Grober E; Brashear HR; Novak G; Ernstrom K; Raman R; Aisen PS; Sperling R; Romano G; Henley D
J Prev Alzheimers Dis; 2022; 9(2):255-261. PubMed ID: 35542998
[TBL] [Abstract][Full Text] [Related]
8. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
[TBL] [Abstract][Full Text] [Related]
9. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
[TBL] [Abstract][Full Text] [Related]
10. Social Engagement and Amyloid-β-Related Cognitive Decline in Cognitively Normal Older Adults.
Biddle KD; d'Oleire Uquillas F; Jacobs HIL; Zide B; Kirn DR; Rentz DM; Johnson KA; Sperling RA; Donovan NJ
Am J Geriatr Psychiatry; 2019 Nov; 27(11):1247-1256. PubMed ID: 31248770
[TBL] [Abstract][Full Text] [Related]
11. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
12. Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease.
Baker JE; Lim YY; Jaeger J; Ames D; Lautenschlager NT; Robertson J; Pietrzak RH; Snyder PJ; Villemagne VL; Rowe CC; Masters CL; Maruff P
J Alzheimers Dis; 2018; 65(3):977-988. PubMed ID: 30103330
[TBL] [Abstract][Full Text] [Related]
13. Mayo-PACC: A parsimonious preclinical Alzheimer's disease cognitive composite comprised of public-domain measures to facilitate clinical translation.
Stricker NH; Twohy EL; Albertson SM; Karstens AJ; Kremers WK; Machulda MM; Fields JA; Jack CR; Knopman DS; Mielke MM; Petersen RC
Alzheimers Dement; 2023 Jun; 19(6):2575-2584. PubMed ID: 36565459
[TBL] [Abstract][Full Text] [Related]
14. Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5.
Papp KV; Rentz DM; Orlovsky I; Sperling RA; Mormino EC
Alzheimers Dement (N Y); 2017 Nov; 3(4):668-677. PubMed ID: 29264389
[TBL] [Abstract][Full Text] [Related]
15. Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease.
Lim YY; Kalinowski P; Pietrzak RH; Laws SM; Burnham SC; Ames D; Villemagne VL; Fowler CJ; Rainey-Smith SR; Martins RN; Rowe CC; Masters CL; Maruff PT
JAMA Neurol; 2018 Apr; 75(4):488-494. PubMed ID: 29356823
[TBL] [Abstract][Full Text] [Related]
16. Two-Year Prognostic Utility of Plasma p217+tau across the Alzheimer's Continuum.
Feizpour A; Doré V; Doecke JD; Saad ZS; Triana-Baltzer G; Slemmon R; Maruff P; Krishnadas N; Bourgeat P; Huang K; Fowler C; Rainey-Smith SR; Bush AI; Ward L; Robertson J; Martins RN; Masters CL; Villemagne VL; Fripp J; Kolb HC; Rowe CC
J Prev Alzheimers Dis; 2023; 10(4):828-836. PubMed ID: 37874105
[TBL] [Abstract][Full Text] [Related]
17. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.
Donohue MC; Sperling RA; Petersen R; Sun CK; Weiner MW; Aisen PS;
JAMA; 2017 Jun; 317(22):2305-2316. PubMed ID: 28609533
[TBL] [Abstract][Full Text] [Related]
18. Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.
Doraiswamy PM; Sperling RA; Johnson K; Reiman EM; Wong TZ; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Joshi AD; Lu M; Grundman M; Mintun MA; Skovronsky DM; Pontecorvo MJ; ;
Mol Psychiatry; 2014 Sep; 19(9):1044-51. PubMed ID: 24614494
[TBL] [Abstract][Full Text] [Related]
19. The Computerized Cognitive Composite (C3) in an Alzheimer's Disease Secondary Prevention Trial.
Papp KV; Rentz DM; Maruff P; Sun CK; Raman R; Donohue MC; Schembri A; Stark C; Yassa MA; Wessels AM; Yaari R; Holdridge KC; Aisen PS; Sperling RA
J Prev Alzheimers Dis; 2021; 8(1):59-67. PubMed ID: 33336226
[TBL] [Abstract][Full Text] [Related]
20. Development of a Cognitive Composite for Preclinical Alzheimer's Disease in Korean Older Adults.
Kim M; Yi D; Byun MS; Ahn H; Jung JH; Kong N; Chang Y; Choi H; Choi J; Kim K; Jung G; Lee DY;
J Alzheimers Dis; 2023; 96(2):633-641. PubMed ID: 37807780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
